Chattagram Maa-O-Shishu Hospital Medical College Journal
Volume 24, Issue 1, January 2025

Editorial

The Alarming Rise in Antifungal Medication Resistance and Its Prospects

Rozina Hoque[1*]

[1]Department of Pharmacology & Therapeutics
Chattagram Maa-O-Shishu Hospital Medical College
Chattogram, Bangladesh.

At present, the most important issue that is being neglected most is the alarming rise of antifungal drug resistance. Along with the pace of resistance, the development of new antifungal drug is not being produced to cover this damaging situation. This grave situation is being taken to further aggravating by continuing the use of currently available antifungals in clinical and agricultural contexts, which has expedited resistance and complicated treatment approaches. The only way to fight against this epidemic is prioritization of antifungal stewardship and the development of novel diagnostic and therapeutic strategies.

Resistance Rates are Increasing

The emergence of drug-resistant fungus species, such Candida auris, highlights the gravity of the situation. These fungi's high mortality rates and association with invasive infections make them a major public health risk. One well-known characteristic of Candida auris is its resistance to several antifungal drugs, which makes infection treatment difficult[1].Triazoles are among the most often used classes of antifungals, and they are particularly prone to resistance. One of the main causes of this is their widespread and usually irrational use in both agriculture and healthcare[1]. It is particularly concerning when antifungals used for crop preservation overlap with those used for clinical purposes since they can aid in the selection of resistant fungus strains that spread to humans.

Issues with Drug Development

The development of antifungal drugs is stalled, which exacerbates the resistance problem. Despite the increasing demand for innovative antifungal treatments, the pharmaceutical sector has been sluggish to produce new drugs. A major contributing factor to this slowness is the high development expenses and strict regulations that postpone the release of new medications onto the market[2]. There aren't many antifungal classes available, and a lot of fungal infections show innate or acquired resistance to them. In light of the fungi's ongoing evolution and adaptation, it is imperative to investigate novel agents with distinct modes of action[3].

Antifungal Stewardship's Role

It is impossible to overestimate the significance of antifungal stewardship in light of these issues. Patient outcomes can be enhanced and the formation of resistance strains can be considerably decreased by putting in place stewardship programs that encourage the prudent use of antifungals in clinical settings[4,1]. Adequate prescribing procedures are only one aspect of effective stewardship; another is the optimization of antifungal dosage and duration. Furthermore, prompt diagnosis and therapy depend on accurate and quick antifungal susceptibility testing. Sadly, the speed and effectiveness required for the best treatment of fungal infections are frequently lacking in present diagnostic techniques[5].

*Correspondence to:
Dr. Rozina Hoque
Professor
Department of Pharmacology & Therapeutics
Chattagram Maa-O-Shishu Hospital Medical College
Chattogram, Bangladesh.
Mobile : +88 01534 56 57 30
Email : rozina.hoq@gmail.com

Date of Submission : 12.12.2024
Date of Acceptance : 23.01.2025

www.banglajol.info/index.php/CMOSHMCJ

There is yet hope despite these overwhelming obstacles. There are plans to create new antifungal medicines, and improvements in diagnostic technology could lead to more accurate and quick susceptibility testing. Nonetheless, the persistent abuse of currently available antifungals and the sluggish rate of innovation pose a hazard to the advancement of resistance management.

Antifungal management and the advancement of innovative therapeutic approaches must be given top priority by the international health community. Antifungal resistance is becoming a serious danger that could have catastrophic effects on public health if nothing is done.

REFERENCES

1. Singh G, Xess I et al. Antifungal Resistance: Current Concepts. In: Thomas, S. (eds) Antimicrobial Resistance. Springer, Singapore. https://doi.org/10.1007/978-981-15-3658-8_7.
2. Georgios Schinas, Georgios Schinas, Georgios Schinas. Antifungal pipeline: Is there light at the end of the tunnel? World Journal of Clinical Cases. doi: 10.12998/wjcc.v12.i16.2686
3. Martin Hoenigl, Amir Arastehfar, Maiken Cavling, Arendrup R, Brüggemann, Agostinho, Carvalho., Tom et al. Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease.. Clinical Microbiology Reviews. 2024. doi: 10.1128/cmr.00074-23.
4. David W, Denning. Antifungal drug resistance: An update. European Journal of Hospital Pharmacy. 2022. doi: 10.1136/ejhpharm-2020-002604.
5. Christopher Heuer, Christopher Heuer, Janina Bahnemann, Thomas Scheper, Ester Segal. Paving the Way to Overcome Antifungal Drug Resistance: Current Practices and Novel Developments for Rapid and Reliable Antifungal Susceptibility Testing. 2021. doi: 10.1002/SMTD.202100713.